DOVA - Dova Pharmaceuticals' Recent Advancements Will Be A Strong Lift For Doptelet Sales
Dova Pharmaceuticals (DOVA) was able to obtain FDA approval for its supplemental New Drug Application ((NDA)) for Doptelet for adults with chronic immune thrombocytopenia ((ITP)). This expands upon the label to its first approval of Doptelet for patients with chronic liver disease ((CLD)). To put focus in the newly approved indication, the biotech has chosen to expand its partnership with Salix Pharmaceuticals. Salix is a subsidiary of Bausch Health (BHC). The company is looking to expand its opportunity with Doptelet in the chemotherapy-induced thrombocytopenia ((CIT)) indication. Finally, there was a European